BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Kensey Nash Corporation (KNSY) Introduces A Novel Biomaterial, Meso BioMatrix(TM) Acellular Porcine Peritoneum, For Plastic And Reconstructive Surgery


4/25/2012 9:24:49 AM

EXTON, Pa., April 24, 2012 /PRNewswire/ -- Kensey Nash Corporation (Nasdaq: KNSY), a leading medical technology company that provides innovative resorbable biomaterial technology for a wide range of medical procedures, today announced the achievement of several milestones for its Meso BioMatrix surgical mesh including the first clinical implant of the product. The Meso BioMatrix product is indicated for use in the United States for implantation to reinforce soft tissue where weakness exists in patients requiring soft tissue repair and reinforcement in plastic and reconstructive surgery. The procedure was performed by Dennis Hammond, M.D. of Partners in Plastic Surgery in Grand Rapids, Michigan. "The Meso BioMatrix product offers several advantages for use in plastic and reconstructive surgery including strength with just the right amount of pliability, and easy re-draping around corners and complex contours. It will serve as an excellent adjunct in plastic and reconstructive surgery," commented Dr. Hammond.

Kensey Nash will be exhibiting the Meso BioMatrix product May 5th-7th at the American Society of Aesthetic Plastic Surgery Meeting in Vancouver, BC.

The Meso BioMatrix surgical mesh is manufactured using Kensey Nash's proprietary Optrix process, which gently disinfects tissues, inactivates viruses and removes cells while preserving extracellular matrix (ECM) components. It is a unique tissue derived from porcine peritoneum, with a thinner profile, and desirable handling characteristics. Pre-clinical studies have shown more rapid cellular infiltration when compared to dermis based xenograft materials[1].

In addition, Kensey Nash has received 510k clearance for its Meso BioMatrix Wound Matrix. This clearance allows for the use of the Meso BioMatrix device in the management of topical wounds. Next steps for the technology include CE Mark submissions for both wound and breast surgery applications, and the initiation of an Investigational Device Exemption (IDE) feasibility clinical study for the use of Meso BioMatrix for soft tissue reinforcement in two-stage post-mastectomy breast reconstruction surgery. The Company has received conditional approval on the IDE protocol from the FDA and has begun clinical site qualifications.

"The Meso BioMatrix products and the previously launched porcine dermis products demonstrate the versatility of the OPTRIX processing technology to provide a full spectrum of ECM products with a diverse range of properties for multiple surgical applications. Surgeons have responded favorably to now having an option of biologic materials to meet an array of surgical needs. We anticipate that these efforts will allow Kensey Nash to explore various partnership opportunities in these growing biologic markets," commented Doug Evans, Chief Operating Officer.

About Kensey Nash Corporation. Kensey Nash Corporation is a medical device company primarily focused on regenerative medicine utilizing its proprietary collagen and synthetic polymer technology. The Company is recognized as a leader for innovative product development and unique technology in the field of resorbable biomaterials. The Company has an extensive range of products, which are sold through strategic partners in multiple medical markets, including, the cardiology, orthopaedic, sports medicine, spine, endovascular and general surgery markets.

Cautionary Note for Forward-Looking Statements. This press release contains forward-looking statements that reflect the Company's current expectations about its prospects and opportunities. The Company has tried to identify these forward looking statements by using words such as "expect," "anticipate," "estimate," "plan," "will," "would," "forecast," "believe," "guidance," "projection" or similar expressions, but these words are not the exclusive means for identifying such statements. The Company cautions that a number of risks, uncertainties and other important factors could cause the Company's actual results to differ materially from those in the forward-looking statements including, without limitation, the Company's continued success in its research and development efforts in its cartilage repair and extracellular matrix technologies programs, the Company's ability to enter into new partnering relationships with respect to its extracellular matrix products and the success of existing and new partners in selling the Company's extracellular matrix products, the completion of additional clinical trials in both the U.S. and Europe to support regulatory approval of future generations of its products and competition from other technologies, current economic conditions, and foreign currency fluctuations. For a detailed discussion of factors that could affect the Company's future operating results, please see the Company's SEC filings, including the disclosures under "Risk Factors" in those filings. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.



[1] Data on file at Kensey Nash

Meso BioMatrix and Optrix are trademarks of Kensey Nash Corporation

SOURCE Kensey Nash Corporation



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES